| Literature DB >> 23840729 |
Jayne Webster1, Kassoum Kayentao, Jane Bruce, Sory I Diawara, Amadou Abathina, Alhassane Ag Haiballa, Ogobara K Doumbo, Jenny Hill.
Abstract
INTRODUCTION: The objectives of the study were to evaluate the health system effectiveness of ANC for the delivery of a dose of IPTp and an ITN to women attending ANC during eligible gestation, and to identify the predictors of systems effectiveness.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23840729 PMCID: PMC3695962 DOI: 10.1371/journal.pone.0067520
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1Systems effectiveness algorithm for IPTp-SP and ITNs.
Descriptions of the potential predictors included in the univariate analyses.
| Indicator | Description | Source |
|
| ||
| Age group | Age | 1 |
| Marital status | Single (incl. engaged), married, divorced | 1 |
| Education | ‘Formal’ with primary lowest level | 1 |
| Ethnicity | 6 named response categories+other | 1 |
| Religion | 3 named response categories+other | 1 |
| Socio economic status | Questions on a range of household assets | 1 |
|
| ||
| Months pregnant | On the day of the survey | 1 |
| Number of children | Live children only | 1 |
| Visit number | Number of visits to ANC including the current one | 1 |
|
| ||
| Cadre of health worker in consultation | Based on previous enrolment of health workers | 3 |
|
| ||
|
| ||
| Morning consultation | Consultation between 8 am and 12 pm | 3 |
| Palpation | Palpation of the abdomen in ANC consultation | 3 |
| Prescribed rhesus test | Prescribed during ANC consultation | 4+/−5 |
| Total time spent in consultation | From entry to completion of ANC consultation | 3 |
| Had HIV PMTCT consultation | Entered the designated room and was seen by a health worker and/or HIV was discussed during ANC | 3 |
| Given ITN in consultation | Was offered and took an ITN | 3 |
|
| ||
| Reason for visit | Routine ANC visit alone, or also because of illness | 1 |
| Suggest a lab test during consultation | Any lab test suggested during ANC consultation | 4+/−5 |
| Prescribed syphilis test | During ANC, or PMTCT consultations | 4+/−5 |
| Report illness at consultation | Any illness reported by the woman during consultation | 2 |
| Consult malaria | Woman reports that she has malaria at consultation | 2 |
| Has symptoms of malaria | Woman reports that she has malaria, fever, shivers, or chills at ANC | 2 |
| Woman reports symptoms of STI/UTI | Woman reports vaginal discharge, dysuria or UTI at ANC | 2 |
| HIV in PMTCT | Tested for HIV in PMTCT | 2 |
|
| ||
| Pay for registration | Any money paid in registration | 3+/−5 |
| Pay for consultation | Any money paid in consultation | 3+/−5 |
| Pay for medicines | Any money paid for medicines | 1 |
| Amount paid for medicines | Total amount paid for medicines | 1 |
| Spent money on travel | Any money spent on travel to and from the facility | 1 |
| Amount spent on travel | Amount of money spent on travel to and from the facility | 1 |
| Money expenditure in the facility | Any money spent in the facility during this visit | 1 |
| Total expenditure | Total amount of money spent in the facility during this visit | 1 |
Source Key.
1 = response of pregnant woman to a question by a fieldworker; 2 = response of pregnant woman to a question from a health worker; 3 = action observed by fieldworker; 4 = heard by a fieldworker during observations; 5 = written information/data observed by fieldworker; PMTC, Prevention of Mother to Child Transmission; ITN, Insecticide Treated Net; STI, sexual transmitted infection; UTI, Urinary Tract Infection; HIV, human immunodeficiency virus; ANC, Antenatal clinic;
Characteristics of health facilities.
| 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | |
| Level | CSRef | CSCom | CSCom | CSCom | CSCom | Dispensary | CSCom | CSCom | CSCom | CSCom |
| No. Staff in ANC | 6 | 4 | 3 | 3 | 2 | 3 | 2 | 3 | 3 | 7 |
| Have lab | yes | no | no | No | No | no | yes | no | no | yes |
| Have a pharmacy | yes | yes | yes | yes | yes | no | no | yes | yes | yes |
| ANC registrants | 1,039 | 880 | 841 | 756 | 700 | 105 | 318 | 757 | 381 | 1,279 |
| ANC attendees | 2,811 | 1,871 | 1,938 | 1,642 | 1,349 | 165 | 637 | 1,302 | 714 | 1,885 |
| Distance from CSRef (Km) | – | 5 | 50 | 45 | 120 | 15 | 10 | 150 | 20 | 5 |
| No. Of observations | 259 | 96 | 43 | 60 | 88 | 64 | 48 | 44 | 47 | 29 |
attending for the first time during the current pregnancy;
attending for the first time or multiple times during the current pregnancy; *during 2008.
CSRef; Reference Health Centre; CSCom, Community Health Centre; ANC, antenatal clinic; Km, kilometre;
No., number.
Characteristics of pregnant women attending the CSRef and the CSComs.
| Characteristic | CSRef (N = 259) | CSComs (N = 521) | |||
| n | % | n | % | p | |
| Age group | 0.04 | ||||
| <20 | 67 | 25.9 | 121 | 21.9 | |
| 20–29 | 135 | 52.1 | 247 | 47.8 | |
| 30–39 | 51 | 19.7 | 139 | 27.4 | |
| 40–49 | 6 | 2.3 | 14 | 2.9 | |
| Education | 0.004 | ||||
| None | 90 | 34.7 | 292 | 56.3 | |
| Primary | 106 | 40.9 | 198 | 39.2 | |
| Primary + | 63 | 24.3 | 31 | 4.5 | |
| Marital status | 0.31 | ||||
| Married | 229 | 89.1 | 469 | 92.5 | |
| Single | 27 | 10.5 | 44 | 7.3 | |
| Divorced | 1 | 0.4 | 1 | 0.2 | |
| Ethnic group | 0.01 | ||||
| Bambara | 100 | 38.6 | 271 | 52.9 | |
| Peuhl (Fulani) | 40 | 15.4 | 73 | 15.4 | |
| Other | 119 | 45.9 | 177 | 31.7 | |
| Religion | 0.44 | ||||
| Muslim | 253 | 98.4 | 499 | 96.9 | |
| Christian | 4 | 1.6 | 10 | 1.8 | |
| Other | 0 | – | 7 | 1.3 | |
| SES group | 0.0002 | ||||
| 1 poorest | 6 | 2.3 | 147 | 28.2 | |
| 2 very poor | 19 | 7.4 | 134 | 27.4 | |
| 3 poor | 37 | 14.5 | 118 | 24.8 | |
| 4 less poor | 90 | 35.2 | 61 | 12.0 | |
| 5 least poor | 104 | 40.6 | 48 | 7.6 | |
| Number of Children | 0.0001 | ||||
| 0 | 75 | 29.0 | 119 | 21.6 | |
| 1 | 73 | 28.2 | 98 | 18.9 | |
| 2–4 | 85 | 32.8 | 236 | 45.5 | |
| 5+ | 26 | 10.0 | 68 | 14.1 | |
| Gestational age | 0.16 | ||||
| 1–3 months | 39 | 16.9 | 56 | 11.6 | |
| 4–6 months | 100 | 43.3 | 205 | 43.3 | |
| 7–9 months | 92 | 39.8 | 199 | 45.1 | |
| ANC Visit number | 0.06 | ||||
| 1 | 110 | 42.5 | 280 | 51.2 | |
| 2 | 66 | 25.5 | 133 | 26.2 | |
| 34≥5 | 413111 | 15.812.04.2 | 622521 | 13.45.04.3 | |
| Reason for visit | 0.006 | ||||
| Routine ANC | 188 | 72.6 | 417 | 80.5 | |
| Routine ANC+ill | 71 | 27.4 | 98 | 19.5 | |
Notes:
Primary+ = any level above primary (secondary, tertiary etc).
CSRef, Reference Health Centre; CSCom, Community Health Centre; n, number of events; N, sample size; ANC, Antenatal clinic;
Figure 2Cumulative effectiveness of delivery of IPTp during 1st ANC visit by women 4 to 8 months pregnant.
Intermediate process 1 = attend ANC consultation; Intermediate process 2 = given SP during ANC consultation; Intermediate process 3 = given 3 tablets SP; Intermediate process 4 = take SP by DOT (A); or take SP by DOT or have 3 tablets on exit and can report correctly how they will be taken (B).
Cumulative and intermediate process effectiveness of delivery of IPTp-SP amongst those 4 to 8 months pregnant.
| 1st visit | 2nd visit | |||||||||||||
| CSRef | CSCom | CSRef | CSCom | |||||||||||
| Intermed | Cum | Intermed | Cum | Intermed | Cum | Intermed | Cum | |||||||
| n | % | n | % (95% CI) | p | n | % | n | % 95% CI | p | |||||
|
| ||||||||||||||
| Attended ANC | 61 | 189 | 48 | 109 | ||||||||||
| Given SP during consultation | 39 | 63.9 | 63.9 | 141 | 74.0(62.0, 83.3) | 0.09 | 74.0 | 25 | 52.1 | 52.1 | 81 | 72.4 (49.6,87.5) | 0.07 | 72.4 |
| Given 3 tablets | 39 | 100.0 | 63.9 | 136 | 96.5(89.8, 98.8) | 0.59 | 71.4 | 25 | 100 | 52.1 | 79 | 97.1 (88.5,99.3) | 0.80 | 70.4 |
| Took SP by DOT | 0 | 0 | 0 | 55 | 34. 3(10.5, 69.8) | 0.36 | 24.5 | 1 | 4 | 2.1 | 31 | 36.0 (10.4,73.3) | 0.001 | 25.4 |
|
| ||||||||||||||
| Attended ANC | 61 | 189 | 48 | 109 | ||||||||||
| Given SP during consultation | 39 | 63.9 | 63.9 | 141 | 74.0(62.0, 83.3) | 0.09 | 74.0 | 25 | 52.1 | 52.1 | 81 | 72.4 (49.6,87.5) | 0.07 | 72.4 |
| Given 3 tablets | 39 | 100.0 | 63.9 | 136 | 96.5(89.8, 98.8) | 0.59 | 71.4 | 25 | 100 | 52.1 | 79 | 97.1 (88.5,99.3) | 0.59 | 70.4 |
| Has SP tablets on exit | 35 | 89.7 | 57.4 | 74 | 59.5(27.4, 85.1) | 0.01 | 44.3 | 24 | 96 | 50.0 | 45 | 60.7 (26.9, 86.6) | 0.004 | 42.7 |
| Report will take 3 tablets | 34 | 97.1 | 55.7 | 72 | 97.0(90.3, 99.1) | 0.90 | 42.0 | 21 | 87.5 | 43.8 | 45 | 100 | 0.004 | 42.7 |
|
| ||||||||||||||
| Report will take 3 tablets & has tabletson exit or took SP by DOT | 34 | 87.2 | 55.7 | 127 | 91.9(82.2, 96.5) | 0.23 | 66.7 | 22 | 88 | 45.8 | 76 | 96.7 (83.9, 99.4) | 0.08 | 68.1 |
| Told when to return for next dose | 8 | 23.5 | 13.1 | 27 | 18.8(9.3, 34.5) | 0.44 | 12.3 | 1 | ||||||
| Told to return in 4 to 5 weeks | 8 | 100 | 13.1 | 24 | 88.2(61.7, 97.2) | 0.51 | 10.8 | 1 | ||||||
Notes:
CSRef, Reference Health Centre; CSCom, Community Health Centre; n, number of events; CI, Confidence Interval; Cum, cumulative process; Intermed, Intermediate process; DOT, Direct Observed Treatment; ANC, Antenatal Clinic; SP, Sulphadoxine-pyrimethamine.
Figure 3Cumulative effectiveness of delivery of ITNs during 1st ANC visit by women of any gestation.
Intermediate process 1 = attend ANC; Intermediate process 2 = offered ITN during ANC consultation; Intermediate process 3 = take ITN.
Cumulative and intermediate process effectiveness of delivery of ITNs amongst pregnant women of any gestation.
| 1st visit | 2nd visit | |||||||||||||
| CSRef | CSCom | CSRef | CSCom | |||||||||||
| Intermed | Cum | Intermed | Cum | Intermed | Cum | Intermed | Cum | |||||||
| n | % | n | %(95% CI) | p | n | % | n | % 95% CI | p | |||||
|
| 110 | 280 | 66 | 133 | ||||||||||
|
| 8 | 7.3 | 7.3 | 232 | 79.4(55.9, 92.2) | <0.0001 | 79.4 | 0 | 0 | 0 | 10 | 6.5 (1.8, 21.1) | – | 6.5 |
|
| 0 | 0 | 0 | 211 | 91.2(63.1,98.4) | – | 72.4 | 0 | 0 | 0 | 10 | 86.2 (1.0, 100) | – | 5.6 |
Notes:
CSRef, Reference Health Centre; CSCom, Community Health Centre; n, number of events; CI, Confidence Interval; ANC, Antenatal Clinic; ITN, Insecticide Treated Net.
Intermed = Intermediate process effectiveness; Cum = cumulative effectiveness.
Unadjusted and adjusted predictors of receiving SP during consultation.
| Potential predictors | CSRef | CSCom | ||||||||
| Unadjusted | Adjusted | Unadjusted | Adjusted | |||||||
| n | OR (95% CI) | p | OR (95% CI) | p | n | OR (95% CI) | p | OR (95% CI) | p | |
|
| ||||||||||
|
| ||||||||||
| None | 55 | 1.0 | 0.31 | 199 | 1.0 |
| 1.0 | <0.001 | ||
| Primary | 74 | 0.93 (0.46, 1.88) | 136 | 1.42 (0.64, 3.15) | 1.56 (0.57, 4.26) | |||||
| Primary + | 37 | 1.70 (0.73, 3.93) | 19 | 0.37 (0.13, 1.03) | 0.25 (0.16, 0.41) | |||||
|
| ||||||||||
|
| ||||||||||
| 4–6 months | 100 | 1.0 |
| 1.0 | 0.002 | 205 | 1.0 |
| 1.0 | 0.03 |
| 7–8months | 66 | 0.24 (0.12, 0.48) | 0.24 (0.09, 0.60) | 149 | 0.25 (0.12, 0.56) | 0.34 (0.13, 0.88) | ||||
|
| ||||||||||
| 3 | 61 | 1.0 |
| 1.0 | 0.22 | 54 | 1.0 |
| 1.0 | 0.26 |
| 2 | 48 | 6.65 (2.92, 15.15) | 2.14 (0.29, 16.15) | 109 | 4.38 (1.54, 12.41) | 2.05 (0.66, 6.33) | ||||
| 1 | 57 | 4.08 (1.74, 9.56) | 2.47 (0.89, 6.88) | 189 | 4.04 (1.28, 12.75) | 3.03 (0.81, 11.34) | ||||
|
| ||||||||||
|
| 162 | 1.04 (1.01, 1.08) |
| 1.04 (0.99, 1.08) | 0.11 | 348 | 0.99 (0.98, 1.00) | 0.17 | ||
|
| ||||||||||
| No | 150 | 1.0 |
| 1.0 | 0.16 | 313 | 1.0 | 0.92 | ||
| Yes | 16 | 4.03 (1.24, 13.08) | 2.65 (0.68,10.27) | 41 | 0.95 (0.32, 2.85) | |||||
|
| ||||||||||
| ANC | 121 | 1.0 |
| 1.0 | 0.13 | 290 | 1.0 |
| 1.0 | 0.04 |
| ANC & illness | 45 | 0.37 (0.18, 0.78) | 0.49 (0.20, 1.22) | 63 | 0.52 (0.26, 1.03) | 0.39 (0.16, 0.97) | ||||
|
| ||||||||||
| No | 145 | 1.0 |
| 1.0 | 0.08 | 306 | 1.0 | 0.29 | ||
| Yes | 21 | 0.33 (0.11, 0.94) | 0.33 (0.09, 1.13) | 48 | 0.66 (0.29, 1.51) | |||||
|
| ||||||||||
| No | 44 | 1.0 | 0.27 | 92 | 1.0 |
| 1.0 | 0.04 | ||
| Yes | 120 | 1.49 (0.73, 3.01) | 260 | 1.54 (0.97, 2.46) | 1.67 (1.03, 2.71) | |||||
|
| ||||||||||
| No | 107 | 1.0 |
| 1.0 | 0.58 | 313 | 1.0 | 0.16 | ||
| Yes | 58 | 2.74 (1.42, 5.30) | 1.77 (0.24, 13.17) | 39 | 1.51 (0.82, 2.78) | |||||
|
| ||||||||||
| No | 110 | 1.0 |
| na | 328 | 1.0 | 0.26 | |||
| Yes | 56 | 3.15 (1.61, 6.16) | 26 | 1.57 (−.67, 3.72) | ||||||
|
| ||||||||||
| 114 | 1.0 |
| 1.0 | 0.62 | 325 | 1.0 | 0.33 | |||
| 52 | 2.87 (1.45, 5.66) | 0.59 (0.07, 4.81) | 29 | 1.23 (0.78, 1.95) | ||||||
|
| ||||||||||
| No | 105 | 1.0 |
| 1.0 | 0.62 | 176 | 1.0 |
| 1.0 | 0.40 |
| Yes | 61 | 3.26 (1.69, 6.29) | 0.58 (0.07, 4.90) | 178 | 1.80 (0.95, 3.41) | 0.82 (0.50, 1.36) | ||||
|
| ||||||||||
| No | 1 | na | 62 | 1.0 |
| 1.0 | 0.07 | |||
| Yes | 165 | 292 | 2.23 (1.01, 4.93) | 2.16 (0.91, 5.14) | ||||||
|
| ||||||||||
| <500 | 79 | 1.0 |
| 1.0 | 0.02 | 69 | 1.0 | 0.19 | ||
| 500–999 | 51 | 4.89 (2.27, 10.49) | 2.57 (0.66, 9.94) | 80 | 2.27 (0.71, 7.33) | |||||
| ≥1000 | 35 | 1.36 (0.60, 3.09) | 0.56 (0.17, 1.86) | 143 | 1.32 (0.62, 2.84) | |||||
|
| ||||||||||
| No | 165 | na | 203 | 1.0 |
| 1.0 | 0.17 | |||
| Yes | 1 | 151 | 2.68 (1.08, 6.67) | 2.01 (0.69, 5.86) | ||||||
Notes:
CSRef, Reference Health Center; CSCom, Community Health Cebter; OR, Odds Ratio; CI, Confidence Interval; n, number of events; PMTCT, Prevention of Mother to Child Transmission; ANC, Antenatal Clinic; ITN, Insecticide Treated Net; Prescr, prescription; na, not applicable;
Unadjusted and adjusted predictors of being given SP by DOT amongst those who were given IPTp-SP in consultation at CSComs.
| Potential predictors | SP DOT | ||||
| Unadjusted | Adjusted | ||||
| n | OR (95% CI) | p | OR (95% CI) | p | |
|
| |||||
|
| |||||
| 1 (poorest) | 109 | 1.0 |
| 1.0 | 0.04 |
| 2 (very poor) | 85 | 1.09 (0.41, 2.89) | 1.16 (0.30, 4.48) | ||
| 3 (poor) | 84 | 0.37 (0.13, 1.10) | 0.38 (0.10, 1.50) | ||
| 4 (less poor) | 41 | 0.29 (0.05, 1.70) | 0.47(0.12, 1.81) | ||
| 5 (least poor) | 29 | 0.20 (0.02, 2.32) | 0.45 (0.34, 5.97) | ||
|
| |||||
|
| |||||
| No | 313 | 1.0 |
| 1.0 | 0.71 |
| Yes | 39 | 0.20 (0.03, 1.14) | 1.67 (0.77, 36.48) | ||
|
| |||||
| No | 328 | 1.0 |
| 1.0 | 0.16 |
| Yes | 26 | 0.07 (0.06, 0.78) | 0.17 (0.01, 2.44) | ||
|
| |||||
| No | 274 | 1.0 |
| 1.0 | 0.09 |
| Yes | 80 | 0.07 (0.01, 0.48) | 0.12 (0.01, 1.52) | ||
|
| |||||
| No | 62 | 1.0 |
| na | |
| Yes | 292 | 0.36 (0.11, 1.21) | |||
|
| |||||
| <500 | 69 | 1.0 |
| 1.0 | 0.01 |
| 500–999 | 80 | 12.57 (2.25, 70.06) | 9.87 (1.28, 75. 71) | ||
| ≥1000 | 143 | 18.17 (5.10, 64.75) | 12.17 (3.14,47.16) | ||
Notes:
SP, Sulphadoxine-pyrimethamine; DOT, Direct Observed Treatment; n, number of events; OR, Odds Ratio, CI, Confidence Interval; SES, Socio-economic Status; Na, not available.
Unadjusted and adjusted predictors of being offered an ITN in the CSComs.
| Potential predictors | ITNs | ||||
| Unadjusted | Adjusted | ||||
| n | OR (95% CI) | p | OR (95% CI) | p | |
|
| |||||
|
| |||||
| 1 (poorest) | 61 | 1.0 |
| 1.0 | 0.002 |
| 2 (very poor) | 54 | 0.55 (0.28, 1.06) | 0.37 (0.14, 0.97) | ||
| 3 (poor) | 42 | 1.19 (0.26, 5.34) | 5.74 (0.14, 229.2) | ||
| 4 (less poor) | 13 | 0.25 (0.53, 1.13) | 0.06 (0.02, 0.17) | ||
| 5 (least poor) | 16 | 0.37 (0.02, 6.64) | 3.15 (0.36, 27.21) | ||
|
| |||||
|
| |||||
| ANC | 148 | 1.0 | 0.02 | 1.0 | 0.24 |
| ANC & illness | 40 | 0.48 (0.26, 0.89) | 0.41 (0.08, 2.05) | ||
|
| |||||
| No | 159 | 1.0 | 0.07 | 1.0 | 0.04 |
| Yes | 30 | 0.56 (0.30, 1.07) | 17.71 (1.24, 252.1) | ||
|
| |||||
| No | 60 | 1.0 | 1.0 | 0.02 | |
| Yes | 127 | 3.78 (1.63, 8.77) | 0.006 | 4.62 (1.35, 15.75) | |
|
| |||||
| No | 171 | 1.0 | 0.05 | 1.0 | 0.07 |
| Yes | 18 | 0.07 (0.01, 0.95) | 0.04 (0.001, 1.47) | ||
|
| |||||
| No | 154 | 1.0 | 0.04 | 1.0 | 0.01 |
| Yes | 35 | 0.11 (0.01, 0.85) | 0.07 (0.01, 0.43) | ||
|
| |||||
| 129 | 1.0 | 0.05 | 1.0 | 0.32 | |
| 31 | 0.93 (0.18, 4.66) | 0.96 (0.09, 10.14) | |||
| 27 | 0.33 (0.14, 0.75) | 0.14 (0.01, 1.91) | |||
|
| |||||
| <500 | 8 | 1.0 | 0.05 | 1.0 | 0.002 |
| 500–999 | 49 | – | – | ||
| ≥1000 | 117 | 5.8 (0.97, 34.57) | 8.79 (2.74, 28.23) | ||
Notes:
n, number of events; OR, Odds Ratio, CI, Confidence Interval; SES, Socio-economic Status; ANC, Antenatal Clinic; HIV, Human Immunodeficiency Virus; PMTCT, Prevention of Mother to Child Transmission.
Design effect and intra cluster correlation of delivery processes amongst the CSRef plus CSComs and the CSComs.
| Delivery process | CSCom | CSCom & CSRef | ||||
| % pregnant women(range) | DE | ICC | % pregnant women (range) | DE | ICC | |
|
| 100 | – | – | 100 (−) | – | – |
|
| 68.0 (40.6–78.9) | 2.86 | 0.033 | 60.9 (40.6–78.9) | 8.08 | 0.139 |
|
| 97.1 (92.3–100) | 1.49 | 0.009 | 97.5 (90–100) | 1.4 | 0.008 |
|
| 33.1 (0–98.3) | 21.11 | 0.353 | 25.3 (0–98.3) | 26.1 | 0.492 |
|
| 93.4 (0 100) | 1.07 | 0.001 | 93.4 (0–100) | 1.07 | 0.001 |
|
| 61.8 (1.8–95.5) | 18.22 | 0.302 | 69.1 (1.8–95.4) | 21.2 | 0.396 |
|
| 98.5 (95.1–100) | 0.83 | −0.003 | 98.1 (95.1–100) | 0.54 | −0.008 |
|
| 99.0 (95.2–100) | 1.0 | 0.0001 | 98.6(95.2–100) | 0.81 | −0.004 |
|
| 14.8 (0–30) | 2.53 | 0.027 | 15.4 (0–30) | 1.87 | 0.018 |
|
| 79.75 (0–100) | 0.58 | −0.007 | 82.7 (0 100) | 0.67 | −0.006 |
|
| 42.59 (0–67.86) | 10.33 | 0.164 | 30.7 (0–67.9) | 27.7 | 0.524 |
Notes:
CSCom, Community Health Centre; CSRef, Reference Health Centre; N = sample size; DE, Design Effect; ICC, intra-class correlation, SP, Sulphadoxine-pyrimethamine; DOT, Direct Observed Treatment; ITN, Insecticide Treated Nets.